Samsrita Labs Limited
BSE: SAMSRITA · Healthcare Service Provider · sector
Key numbers
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 31 companies in Healthcare Service Provider (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹2 cr vs borrowings ₹2 cr (FY26): borrowings are higher by ₹0 cr.
- Net loss in 4 of the last 6 quarters.
- Other income was 23% of net profit in the last 12 months.
- No dividend in the last 5 financial years.
- Price ₹12.13 on 2026-10-26: -52.0% from the 52-week high, +19.5% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -0 | -0 | -5 | -3 | -0 | -0 |
| OPM % | – | – | – | – | -750.0% | – |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -0 | -0 | 0 | 0 | -0 | -0 |
| EPS (₹) | 0.06 | 0.19 | 2.00 | 1.29 | 0.06 | 0.08 |
| Revenue YoY | – | – | ||||
| Profit YoY | – | – |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | – | 0 | 0 | 0 |
| EBITDA | -0 | -1 | -0 | -0 | -9 | -9 |
| Net profit | 2 | -1 | -0 | -0 | -8 | 0 |
| EPS (₹) | 1.01 | -0.48 | -0.17 | 0.18 | 3.99 | 3.43 |
| Revenue growth | 0.0% | – | – | – | – | |
| Profit growth | -147.3% | – | – | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -3.3% | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | -26.5% (2y) | -38.7% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 12 | 12 |
| Borrowings | 2 | 2 |
| Cash & equivalents | 0 | 2 |
| Total assets | 16 | 14 |
| Fixed assets | 0 | 0 |
| Capital work in progress | 0 | 0 |
| Investments | 5 | 0 |
| Receivables | 2 | 0 |
| Inventory | 0 | 0 |
| Payables | 0 | 0 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | -0 | -5 |
| Cash from investing | 0 | 3 |
| Cash from financing | 0 | 3 |
| Capex | 0 | 0 |
| Free cash flow | -0 | -5 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | -2.1% | -69.4% |
| ROCE % | -1.8% | -64.7% |
| Debtor days | – | 395 |
| Inventory days | – | 0 |
| Payable days | – | 394 |
| Cash conversion cycle (days) | – | 1 |
| Working capital days | – | 139 |
Peers in Healthcare Service Provider
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| LALPATHLAB | ₹31,100 cr | 57.2x | 12.4x | 23.1% | 29.6% | 27.9% | +11.1% | 0.71% |
| VIJAYA | ₹14,362 cr | 76.6x | 15.0x | 21.4% | 30.1% | 42.2% | +21.0% | 0.14% |
| METROPOLIS | ₹10,989 cr | 54.5x | 7.3x | 14.2% | 19.7% | 24.2% | +12.8% | 0.19% |
| THYROCARE | ₹7,491 cr | 42.6x | 12.8x | 31.1% | 39.7% | 31.4% | +16.3% | 1.99% |
| NEPHROPLUS | ₹6,095 cr | 71.6x | 5.5x | 6.9% | 13.4% | 22.7% | – | – |
| SURAKSHA | ₹1,628 cr | 45.4x | 6.7x | 15.7% | 25.2% | 31.4% | – | – |
| KRSNAA | ₹1,617 cr | 16.6x | 1.6x | 10.5% | 11.1% | 26.8% | +16.6% | 0.55% |
| 3BBLACKBIO | ₹1,193 cr | 21.2x | 3.7x | 18.7% | 22.8% | 34.9% | +127.8% | 0.29% |
| HEALTHX | ₹857 cr | – | 3.2x | -0.5% | – | – | – | – |
| SAMSRITA | ₹16 cr | 3.5x | 1.4x | 1.1% | -65.0% | -48,361.3% | -3.3% | – |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Healthcare Service Provider |
| Sub-industry | Healthcare Service Provider |
| Symbol | SAMSRITA |
| BSE code | 539267 |
| ISIN | INE579N01018 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.